Skip to main content
NTRA logo

NTRA · Natera, Inc.

Track NTRA — free
$302.00 +13.52 (+4.69%)
Market Cap
$41.83B
Shares
145.00M
Volume · Nov 16 2.34M Avg daily vol (3M) 1.74M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$288.48 Open$313.99 Day$287.83–315.21 52W close$182.65–436.00 Avg vol 30d2.0M Short int6.1M · 4.2% of shares · 4.2d Short vol40% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 12
Registration statement S-3ASR
68,023 shares registered for potential resale

Natera registered 68,023 shares for potential resale by unnamed, non-affiliated selling stockholders. The total includes 45,533 closing shares issued on or about November 10, 2026 and an estimated 22,490 additional shares; Natera receives no proceeds.

Read from the first part of this long document
3 source passages
This prospectus relates to the potential resale from time to time of up to an aggregate of 68,023 shares (“Resale Shares”) of common stock, par value $0.0001 per share, of Natera, Inc. (the “Company”) by certain unnamed, non-affiliated selling stockholders described in this prospectus (the “Selling Stockholders”). The Resale Shares consist of (i) 45,533 shares (the “Closing Shares”) of the Company’s common stock issued to the Selling Stockholders on or about November 10, 2026, in connection with the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of November 2, 2026 (the “Merger Agreement”), by and among the Company, two wholly owned merger subsidiaries of the Company, a privately held company (the “Acquired Company”) and a stockholder representative, and (ii) an estimated 22,490 additional shares that may become issuable to the Selling Stockholders after the closing pursuant to the Merger Agreement (the “Potentially Issuable Shares”) We are not offering or selling any of the Resale Shares and we will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholders pursuant to this prospectus. Open the document at this passage
Nov 10
Investor event
Revenue target reaches $6 billion by 2029

Natera targets $6 billion in revenue by 2029, using $14.50 Signatera ASP versus $12.90 today as an illustrative path. Solomon became CEO immediately, with operating and commercial structures unchanged.

5 source passages
what are the kind of some indicative assumptions one could use to get to $6 billion in revenue by 2029? $14.50 as an ASP for Signatera. Compare that to the current ASP of $12.90. So you have a new CEO, effective immediately. Tell me about Solomon. So our meeting cadences, the decisions that we make, our approach to how we size territories, how we measure performance, none of those things are going to change. We'll have colorectal cancer much quicker than that, but I'm very excited about that as the next chapter for Natera. Open the document at this passage
Nov 9
Investor event
Solomon Moshkevich targets $6 billion revenue in 2029

Natera CEO Solomon Moshkevich targets $6 billion in revenue for 2029; Signatera is expected to generate a little over a billion this year, with the fine study readout expected in the back half of next year.

6 source passages
Solomon Moshkevich, CEO Yeah, so Solomon is the 40th or 41st employee that joined Natera in 2011. The $6 billion 2029 revenue target. As Signatera has evolved from being something that you would use in a targeted setting for colorectal cancer and breast cancer, and evolved to more of a liquid CT scan. Signaterra is going to be something that, you know, there's, you know, a little over a billion in revenue this year. We're very excited about the fine study readout. I expect that next year. Probably back half, right? Open the document at this passage
Nov 5
Earnings call
Solomon succeeds Steve as CEO as revenue guidance rises

Natera says Solomon will succeed Steve as CEO, raising full-year 2026 revenue guidance to $3 billion $5 million-$3 billion $35 million and targeting $6 billion in 2029.

4 source passages
I am stepping down from the CEO role, as now is an excellent time to transition to new leadership for Natera. I'm very pleased to be handing the keys over to my friend and colleague, Solomon. Given the strength of the third quarter, we are raising our full year 2026 revenue guidance to a range of $3 billion $5 million to $3 billion $35 million, up from the $2.85 billion to $2.91 billion on our last call. We're setting the goal to double revenues in the next three years, reaching $6 billion in revenue in 2029. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 34.1% as net loss narrowed 31.6%

Natera reported that total revenues increased $201.8 million, or 34.1%, in the three months ended September 30, 2026, while net loss narrowed 31.6%. For the nine months, revenue was $2,243.4 million and net loss was $212.0 million.

Revenue $793.98M ▲ 34.1% Net loss $59.91M Diluted EPS -$0.42
Read from the MD&A section
4 source passages
Total revenues for the three months ended September 30, 2026 increased by $201.8 million, or 34.1%, when compared to the three months ended September 30, 2025. Net loss | (59,912) | (87,544) | 27,632 | (31.6%) For the nine months ended September 30, 2026, total revenues were $2,243.4 million compared to $1,640.6 million in the nine months ended September 30, 2025. Our net loss for the nine months ended September 30, 2026 and 2025 was $212.0 million and $255.4 million, respectively. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$2.91B
Trailing 12 months
Net income (TTM)
−$164.71M
Trailing 12 months
Revenue growth YoY
+34.1%
Year over year
Operating margin
-9.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
0.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.02B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.0%
Year over year · more shares
Price change (1Y)
+59.0%
Trailing year
Short interest
4.2%
Latest settlement · 4.2 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Q3 revenue grew 34.1%, clinical MRD volume grew more than 56%, and management raised 2026 revenue guidance by $140 million at the midpoint. Underlying gross margin improved, cash increased, the net loss narrowed, HCC coverage was granted, Japan commercialization remained on track, pharma revenue accelerated, and management set a $6 billion 2029 revenue target alongside early-detection milestones.

Bullish
  • + Pharma revenue accelerated sharply, with first-nine-month revenue already up roughly 70% versus all of 2025. new
Bearish
  • − Natera remained unprofitable, reporting a $59.9 million net loss in Q3 2026. new
  • − Reported gross margin declined 24 basis points year over year to 64.7%. new
  • − Total operating expenses increased 19.5% year over year because of headcount growth and higher clinical-trial spending. new
  • − Early cancer detection is consuming more than $100 million while generating no revenue. new
  • − Higher COGS from newer products such as Fetal Focus and Signatera Genome may create short-term gross-margin pressure. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg +6%
above
Price vs 50-day avg −24%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 42%
mid-range
Momentum
relative strength
Strong
1-month return −28%
trailing
6-month return +42%
trailing
YTD return +26%
this year
Relative strength +43%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $379 › 200d $272 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +170 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.19% of shares out · ▲ +3.8% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
875 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Strong
Revenue growth −3%
Y/Y
EPS growth +1%
Y/Y
Free cash flow $109.1M
Balance sheet $995.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 53%
annualized · 1-yr
Max drawdown −34%
past year
ATR 7.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 6
Latest guidance · from the 8-K filed Nov 5, 2026
2026
Total revenue Raised $3.01B – $3.04B
Aug 6, 2026 $2.85B – $2.91B changed to Nov 5, 2026 $3.01B – $3.04B
prior FY $2.31B midpoint +31.0% Y/Y
Selling, general and administrative costs Raised $1.23B – $1.3B
Aug 6, 2026 $1.13B – $1.23B changed to Nov 5, 2026 $1.23B – $1.3B
Research and development costs Raised $825M – $925M
Aug 6, 2026 $800M – $900M changed to Nov 5, 2026 $825M – $925M
Gross margin %1 GAAP 64% – 66%
Gross margin1 GAAP 64% – 66%
2029
Annual revenues $6B
prior FY $2.31B midpoint +160.2% Y/Y
2026 annual
Gross margin % GAAP Maintained 64% – 66%
Aug 6, 2026 64% – 66% changed to Nov 5, 2026 64% – 66%
Previous outlook earlier release · from the Earnings Call filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Revenues · this year $2.85B – $2.91B
Guided vs delivered · last 6 settled
Revenue full year
guided $2.18B – $2.26B
$2.31B Beat +3.9%
Total revenue 2024
guided $1.49B – $1.52B
$1.7B Beat +12.8%
Annual revenue 2023 annual
guided $1.04B – $1.05B
$1.08B Beat +3.8%
Total revenue 2022
guided $810M – $830M
$820.22M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+6% Bullish
Price vs 50-day avg
−24% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
42% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $379 › 200d $272 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +170 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
4.19% of shares out · ▲ +3.8% MoM · 4.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
875 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $183 Now $288 · 42% Range high $436
vs 200-day avg +6% vs 50-day avg -24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
clinical MRD oncology tests 283K Q2 2026 —
Oncology tests processed 296,700 Q2 2026 —
Tests accessioned 1,030,100 Q2 2026 —
Tests processed 1,043,900 Q2 2026 —
Tests reported 985,500 Q2 2026 —
Tests reported in our laboratory 972,000 Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NTRA
Natera, Inc.
this stock
$41.83B +25.9% -2.8% — 4.2%
TMO
Thermo Fisher Scientific Inc.
$256.15B +19.3% +14.5% 36.5 1.3%
DHR
Danaher Corp
$161.75B +0.4% +8.5% 37.6 1.2%
IDXX
Idexx Laboratories Inc
$55.20B +3.6% +10.4% 47.2 3.0%
A
Agilent Technologies, Inc.
$48.75B +27.1% +6.4% 34.0 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
875
% held
87.0%
Net QoQ
-11.0M sh
Top holder
JPMORGAN CHASE & CO
Held Float
View
Held by Funds
Fund positions
751
View
Short & Settlement
Short Interest Rising
Shares short
6.1M
Days to cover
4.2d
Change
+220.6K sh
View
Short Volume
Short vol %
40%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
90
Value
$36.4K
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
48.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Josh Gottheimer
Amount
$1.0K–$15.0K
Traded
Sep 22, 2025
View
Financials
Financials
Revenue (FY)
$2.3B
Net income (FY)
$-208.2M
EPS diluted
$-1.52
View
Filings
SEC Filings
Latest
S-3ASR
Filed
Nov 12, 2026
This year
24

Natera registered 68,023 shares for potential resale by unnamed, non-affiliated selling stockholders. The total includes 45,533 closing shares issued on or about November 10, 2026 and an estimated 22,490 additional shares; Natera receives no proceeds.

View
Proposed Sales
Value
$178.1K
Shares
470
Filed
Nov 3, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Natera Announces Clinical Collabo…
Published
Nov 10, 2026
View

Performance

5D 20D 120D MTD YTD
NTRA -10.0% -27.8% +42.0% -30.4% +25.9%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -8.3% -24.3% +43.4% -28.3% +17.4%
Key facts CIK 1604821 CUSIP 632307104 13F (30d) 826 filings 774 filers Visit website Investor relations